SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Amphista Therapeutics to Present AMX-883 Data at ASH Meeting

The company says it will present data on AMX-883 at the American Society of Hematology annual meeting. The supplied description says AMX-883-mediated BRD9 degradation disrupts hematopoietic transcriptional programs and promotes myeloid.

SquawkNews Desk

Related stories

Canadian Natural Resources Beats Quarterly Profit Estimate M impact | EQUITY | Nov 05, 2026, 09:47 AM UTC Insecticides (India) Q2 Consolidated Net Profit INR 561.7 Million M impact | EQUITY | Nov 05, 2026, 09:45 AM UTC Shanghai International Port Expects October Container Throughput Up 9.8% The company also expects cargo throughput to rise 5.6% year over year. L impact | EQUITY | Nov 05, 2026, 09:45 AM UTC SiTime shares rise 4.2% premarket after Q3 revenue beats estimates M impact | EQUITY | Nov 05, 2026, 09:44 AM UTC Toyota Raises 2027 EPS Outlook as Fiscal Q2 Revenue Rises Toyota's fiscal second-quarter revenue rose, and it raised its 2027 EPS outlook. Shares jumped before the bell. M impact | EQUITY | Nov 05, 2026, 09:43 AM UTC CERT-In Flags Vulnerabilities in Tata Motors’ iRA Apps India’s CERT-In warned that vulnerabilities in Tata Motors’ iRA 2.0 and iRA.ev apps could be exploited to extract embedded sensitive information. M impact | EQUITY | Nov 05, 2026, 09:43 AM UTC